scientifyRESEARCH
research funding database

RESEARCH FUNDING

Human Leukocyte Antigen (HLA) and Killer-cell Immunoglobulin-like Receptor (KIR) Region Genomics in Immune-Mediated Diseases (U01 Clinical Trial Not Allowed | USA)

Share this post

Logo of scientifyRESEARCH and Enago "Author First, Quality First" scientifyRESEARCH recommends English editing and author support services from Enago.
Free trial

The Human Leukocyte Antigen (HLA) and Killer-cell Immunoglobulin-like Receptor (KIR) Region Genomics in Immune-Mediated Diseases (U01 Clinical Trial Not Allowed) funding call from the National Institutes of Health (NIH) supports research that

  1. defines associations between variations in human leukocyte antigen (HLA) and killer cell immunoglobulin-like receptor (KIR) genetic regions and immune-mediated diseases,
  2. elucidates mechanisms underlying these associations with the goal of advancing therapeutic opportunities, and/or
  3. validates association data in order to improve the predictive power of clinical disease screening.

The proposal must provide a Plan for Enhancing Diverse Perspectives (PEDP). Applications are open to researchers in the USA.

The Award provides up 400,000 USD (plus indirect costs) for 5 years.

Opportunity number: RFA-AI-24-017

Letters of intent are due July 20, 2024. Applications are due August 20, 2024.

Adverts. Premium members do not see Google Ads.

Please Login / Subscribe to our premium membership to see the content. Sign up to Free trial to see detailed funding information.

non member

Sign-up for our monthly
research funding newsletter

you can unsubscribe at any time